Cargando…
Anticipated effects of burosumab treatment on long-term clinical sequelae in XLH: expert perspectives
X-linked hypophosphatemia (XLH) is a rare, progressive, genetic disease with multisystem impact that typically begins to manifest in early childhood. Two treatment options exist: oral phosphate in combination with active vitamin D (“conventional therapy”) and a fully human monoclonal anti-FGF23 anti...
Autores principales: | Seefried, Lothar, Duplan, Martin Biosse, Briot, Karine, Collins, Michael T., Evans, Rachel, Florenzano, Pablo, Hawkins, Neil, Javaid, Muhammad Kassim, Lachmann, Robin, Ward, Leanne M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400326/ https://www.ncbi.nlm.nih.gov/pubmed/37547321 http://dx.doi.org/10.3389/fendo.2023.1211426 |
Ejemplares similares
-
Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment
por: Kamenicky, Peter, et al.
Publicado: (2023) -
XLH Matters 2022: Insights and recommendations to improve outcomes for people living with X-linked hypophosphataemia (XLH)
por: Seefried, Lothar, et al.
Publicado: (2023) -
SUN-523 XLH Outcome Data from One Centre Experience with Burosumab
por: Cheung, Moira, et al.
Publicado: (2019) -
SUN-356 Burosumab Resulted in Greater Clinical Improvements Compared with Higher-dose Conventional Therapy in Children with X-linked Hypophosphatemia (XLH)
por: Imel, Erik A, et al.
Publicado: (2020) -
OR13-2 Burosumab Resulted in Greater Improvement in Rickets Than Conventional Therapy in Children with X-Linked Hypophosphatemia (XLH)
por: Imel, Erik, et al.
Publicado: (2019)